The G801A Polymorphism in the CXCL12 Gene and Risk of Breast Carcinoma: Evidence from a Meta-Analysis Including 2,931 Subjects

  • Xia, Yong ;
  • Guo, Xu-Guang ;
  • Ji, Tian-Xing
  • Published : 2014.03.30


More and more evidence indicates that the G801A polymorphism in the CXCL12 gene might be associated with susceptibility to breast carcinoma in humans being. However, individually published results have been inconsistent. The purpose of this meta-analysis was to investigate the association between the G801A polymorphism in the CXCL12 gene and breast carcinoma risk. A complete search strategy was done by the electronic databases including PubMed and Chinese Biomedical Literature Database. A meta-analysis including seven individual studies was carried out in order to explore the association between the G801A polymorphism in the CXCL12 gene polymorphisms and breast carcinoma. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (95%CIs) between the G801A polymorphism in the CXCL12 gene and breast carcinoma risk were assessed by the random-effects model. A significant relationship between the G801A polymorphism in the CXCL12 gene and breast carcinoma was discovered in an allelic genetic model (OR: 1.214, 95%CI: 1.085-1.358, p=0.001), a homozygote model (OR: 1.663, 95%CI: 1.240-2.232, p=0.001), a heterozygote model (OR: 1.392, 95%CI: 1.190-1.629, p=0.000), a recessive genetic model (OR: 1.407, 95%CI: 1.060-1.868, p=0.018) and a dominant genetic model (OR: 1.427, 95%CI: 1.228-1.659, p=0.000). On sub-group analysis based on ethnicity, significance was observed between the European group and the mixed group. A significant relationship was found between the G801A polymorphism in the CXCL12 gene and breast carcinoma risk. Individuals with the A allele of the G801A polymorphism in the CXCL12 gene are under a higher risk for breast carcinoma.


Breast carcinoma;breast cancer;meta-analysis;G810A;polymorphism;CXCL12


  1. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  2. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA (2004). Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet, 41,59.
  3. Kontogianni P, Zambirinis CP, Theodoropoulos G, et al (2013). The impact of the stromal cell-derived factor-1-3'A and E-selectin S128R polymorphisms on breast cancer. Mol Biol Rep, 40, 43-50.
  4. Kruszyna L, Lianeri M, Rubis B, et al (2010). CXCL12-3' G801A polymorphism is not a risk factor for breast cancer. DNA Cell Biol, 29, 423-7.
  5. Lin GT, Tseng HF, Yang CH, et al (2009). Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS, 13, 165-72.
  6. Ma XY, Jin Y, Sun HM, et al (2012). CXCL12 G801A polymorphism contributes to cancer susceptibility: a metaanalysis. Cell Mol Biol, 58, 1702-8.
  7. Razmkhah M, Doroudchi M, Ghayumi SM, et al (2005). Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer, 49, 311-5.
  8. Razmkhah M, Talei AR, Doroudchi M, et al (2005). Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett, 225, 261-6.
  9. Shen W, Cao X, Xi L, Deng L (2012). CXCL12 G801A polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep, 39, 2039-44.
  10. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
  11. Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 470-1.
  12. Thakkinstian A, McElduff P, D'Este C, et al (2005). A method for meta-analysis of molecular association studies. Stat Med, 24, 1291-306.
  13. de Oliveira KB, Oda JM, Voltarelli JC, et al (2009). CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. J Clin Lab Anal, 23, 387-93.
  14. Cochran WG (1968). The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics, 24, 295-313.
  15. de Oliveira KB, Guembarovski RL, Guembarovski AM, et al (2013). CXCL12, CXCR4 and IFNgamma genes expression: implications for proinflammatory microenvironment of breast cancer. Clin Exp Med, 13, 211-9.
  16. de Oliveira KB, Guembarovski RL, Oda JM, et al (2011). CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine, 55, 260-5.
  17. Desantis C, Ma J, Bryan L, Jemal A (2014). Breast cancer statistics, 2013. CA Cancer J Clin, 64, 52-62.
  18. Dimberg J, Hugander A, Lofgren S, Wagsater D. (2007). Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med, 19, 11-5.
  19. Donnelly TT, Khater AH, Al-Bader SB, et al (2013). Arab women's breast cancer screening practices: a literature review. Asian Pac J Cancer Prev, 14, 4519-28.
  20. Gong H, Tan M, Wang Y, et al (2012). The CXCL12 G801A polymorphism and cancer risk: evidence from 17 casecontrol studies. Gene, 509, 228-31.
  21. Hassan S, Baccarelli A, Salvucci O, and Basik M (2008). Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res, 14, 446-54.
  22. Hinton CV, Avraham S, Avraham HK (2010). Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis, 27, 97-105.
  23. Chuang LY, Chang HW, Lin MC, Yang CH (2012). Chaotic particle swarm optimization for detecting SNP-SNP interactions for CXCL12-related genes in breast cancer prevention. Eur J Cancer Prev, 21, 336-42.

Cited by

  1. Insulin Promotes Proliferation and Migration of Breast Cancer Cells through the Extracellular Regulated Kinase Pathway vol.15, pp.15, 2014,
  2. The AURKA Gene rs2273535 Polymorphism Contributes to Breast Carcinoma Risk - Meta-analysis of Eleven Studies vol.15, pp.16, 2014,